Intellia Therapeutics (NTLA) Amortizatization of Intangibles (2019 - 2026)
Intellia Therapeutics (NTLA) reported Amortizatization of Intangibles of $535000.0 for Q1 2026, down 76.54% year-over-year from $2.3 million in Q1 2025, and down 85.28% on a QoQ basis from $3.6 million in Q4 2025.
Intellia Therapeutics (NTLA) has 8 years of Amortizatization of Intangibles data on file, last reported at $535000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 76.54% year-over-year to $535000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 246.79% YoY) and the FY2025 annual result came in at $6.2 million, changed N/A from the prior year.
- Amortizatization of Intangibles slipped to $535000.0 in Q1 2026 per NTLA's latest filing, from $3.6 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $7.9 million in Q3 2023 and bottomed at -$19.6 million in Q4 2023.
- The 5-year median for Amortizatization of Intangibles is $1.5 million (2022), against an average of $168000.0.
- Peak annual rise in Amortizatization of Intangibles reached 1061.53% in 2023, while the deepest fall reached 1668.45% in 2023.
- Tracing NTLA's Amortizatization of Intangibles over 5 years: stood at $1.2 million in 2022, then sank by 1668.45% to -$19.6 million in 2023, then surged by 49.29% to -$9.9 million in 2024, then surged by 136.59% to $3.6 million in 2025, then sank by 85.28% to $535000.0 in 2026.
- Per Business Quant, the three latest NTLA Amortizatization of Intangibles figures stand at $535000.0 (Q1 2026), $3.6 million (Q4 2025), and -$1.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 535,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 535,000.00 |
| Mar 31, 2026 | 535,000.00 |
| Dec 31, 2025 | 3.64 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Mar 31, 2025 | 2.28 Mn |
| Sep 30, 2024 | -9.93 Mn |
| Sep 30, 2024 | -9.93 Mn |
| Jun 30, 2024 | 4.65 Mn |
| Jun 30, 2024 | 4.65 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | -19.59 Mn |
| Dec 31, 2023 | -19.59 Mn |
| Sep 30, 2023 | 7.92 Mn |
| Sep 30, 2023 | 7.92 Mn |
| Jun 30, 2023 | 7.10 Mn |
| Jun 30, 2023 | 7.10 Mn |
| Mar 31, 2023 | 4.57 Mn |
| Mar 31, 2023 | 4.57 Mn |
| Dec 31, 2022 | 1.25 Mn |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | -824,000.00 |
| Sep 30, 2022 | -824,000.00 |
| Jun 30, 2022 | -2.00 Mn |
| Jun 30, 2022 | -2.00 Mn |
| Mar 31, 2022 | -2.43 Mn |
| Mar 31, 2022 | -2.43 Mn |
| Dec 31, 2021 | -2.63 Mn |
| Dec 31, 2021 | -2.63 Mn |
| Sep 30, 2021 | -2.10 Mn |
| Sep 30, 2021 | -2.10 Mn |
| Jun 30, 2021 | -1.66 Mn |
| Jun 30, 2021 | -1.66 Mn |
| Mar 31, 2021 | -1.21 Mn |
| Mar 31, 2021 | -1.21 Mn |
| Dec 31, 2020 | -733,000.00 |
| Dec 31, 2020 | -733,000.00 |
| Sep 30, 2020 | -73,000.00 |
| Sep 30, 2020 | -73,000.00 |
| Jun 30, 2020 | 68,000.00 |
| Jun 30, 2020 | 68,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Dec 31, 2019 | -7.02 Mn |
| Dec 31, 2019 | -7.02 Mn |
| Sep 30, 2019 | 667,000.00 |
| Sep 30, 2019 | 667,000.00 |
| Jun 30, 2019 | 1.21 Mn |
| Jun 30, 2019 | 1.21 Mn |
| Mar 31, 2019 | 1.42 Mn |
| Mar 31, 2019 | 1.42 Mn |